1. Scrip
  2. >>Business
  3. >>Financing

Closer To Home: Hong Kong Takes On Nasdaq For China Biotech IPOs

 
• By Brian Yang

Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

Global currency

Another day, another Chinese biotech is poised to go public, this time biosimilar developer Shanghai Henlius Biotech Co. Ltd., which is reportedly preparing for a planned public listing in Hong Kong.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business